LAURUSLABS

Laurus Labs reported Q1 FY20 results, highlighting growth in API manufacturing and expansion into finished dosage forms. Management emphasized R&D investments and strategic partnerships as key drivers of future growth. The company also discussed opportunities in synthesis and ingredients businesses, indicating a diversified approach to revenue streams.

Segment commentary

Active Pharmaceutical Ingredients (APIs)

Growth in ARV and Hepatitis C APIs, with strategic investments in R&D.

Finished Dosage Forms

Expansion into FDF capabilities leveraging existing API strengths.

Synthesis and Ingredients Businesses

Driving growth opportunities in these areas.

Guidance & outlook

Focus on R&D and manufacturing infrastructure to maintain leadership in ARV APIs.
Exploring new therapeutic areas for future growth.

Key takeaways

Strong focus on R&D driving growth in API segment.
Expansion into FDF and synthesis businesses diversifying revenue streams.
Optimistic outlook with strategic investments in infrastructure and new opportunities.

Educational analysis only. Not investment advice. Consult a SEBI-registered advisor before investing. Source: https://nsearchives.nseindia.com/corporate/LAURUSLABS_30072019145232_LaurusLabsQ1FY20ResultsConCallInvite_164.pdf

Full transcript (297 words)

LAURUS LABS LIMITED LAURUS LABS LTD. Q1 FY20 RESULTS CONFERENCE CALL ON MONDAY, AUGUST 05, 2019 AT 11 :00 AM 1ST Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Monday, August 05, 2019 at 11:00 am 1ST. The conference call will be initiated with a brief management discussion on the Q 1 FY20 results which will be declared on August 2, 2019. This will be followed by an interactive Question & Answer session. The call will be hosted by Kotak Institutional Equities. Details of the conference call are as follows: Timing 11:00 am 1ST on Monday, August 5, 2019 Conference dial-in Primary number +91 22 6280 1214 Secondary Number +9.1 7045671221 Available all over India Singapore +6531575746 Hong Kong +85230186877 USA +13233868721 UK +442034785524 -ENDS- For LAURUS LABS L!MITED JULY 30, 2019 LAURUSLabs PAGE2 About Laurus Labs Ltd. Laurus Labs is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APis) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APis in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APis in the ARV therapeutic area. Laurus Labs also forayed into Finished Dosages Forms capabilities on the back of existing strengths in APis. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. Corporate Identification No: L24239AP2005PLC047518. For further information please contact Monish Shah Pavan Kumar Nerella Laurus Labs Limited Laurus Labs Limited Tel: +91 40 3980 4366 Tel: +91 40 3980 4380 Email: monish.shah@LaurusLabs.Com Email: pavankumar.n@lauruslabs.com For LAURUS LABS L!MITED JULY 30,2019